- Conditions
- Obesity, Visceral, Cardiovascular Diseases, Fat Disorder
- Interventions
- Liraglutide, Placebo
- Drug
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 35 Years and older
- Enrollment
- 235 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- Dallas, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–46
of 22
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Anesthesia, Neuromuscular Blockade
- Interventions
- Saline 0.06 ml/kg, Rocuronium 0.2 mg/kg, Rocuronium 0.4 mg/kg, Rocuronium 0.6 mg/kg
- Drug
- Lead sponsor
- Medtronic - MITG
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 1
- States / cities
- Burlington, Vermont
- Conditions
- Anesthesia
- Interventions
- Normal Saline, Lactated Ringer, Normosol-R Inj
- Drug
- Lead sponsor
- Nationwide Children's Hospital
- Other
- Eligibility
- 10 Years to 21 Years
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Pain, Postoperative, Ankle Fractures
- Interventions
- Ropivacaine, Epinephrine, Morphine, 0.9% sodium chloride solution
- Drug
- Lead sponsor
- University of Iowa
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Iowa City, Iowa
- Conditions
- Blood Loss, Surgical
- Interventions
- Ecallantide, Placebo
- Drug
- Lead sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Aurora, Colorado + 8 more
- Conditions
- Endometriosis, Post Operative Pain
- Interventions
- Ketamine, Placebo
- Drug
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Dry Eye Disease, Endothelial Cell
- Interventions
- Cyclosporine ophthalmic solution, 0.1%, Saline solution, 0.6%
- Drug
- Lead sponsor
- Novaliq GmbH
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 204 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 6
- States / cities
- Newport Beach, California • Torrance, California • Garner, North Carolina + 3 more
- Conditions
- VTE Prophylaxis With Anticoagulation After Total Knee Replacement Surgery
- Interventions
- JNJ-64179375 0.3 mg/kg, JNJ-64179375 0.6 mg/kg, JNJ-64179375 1.2 mg/kg, JNJ-64179375 (Dose to be Determined), JNJ-64179375 A mg/kg, JNJ-64179375 B mg/kg, JNJ-64179375 C mg/kg, JNJ-64179375 D mg/kg, Placebo JNJ-64179375, Apixaban placebo, Apixaban 2.5 mg
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 308 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 7
- States / cities
- Phoenix, Arizona • Torrance, California • Englewood, Colorado + 4 more
- Conditions
- Rib Fractures, Pain, Acute
- Interventions
- Dexmedetomidine, Placebo
- Drug · Other
- Lead sponsor
- University of California, Irvine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Orange, California
- Conditions
- Escherichia Infection
- Interventions
- B7A (ETEC challenge strain), CssBA, dmLT, Placebo
- Other · Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland • Cincinnati, Ohio
- Conditions
- Allergic Reactions
- Interventions
- Valortim and selected Components, Valortim and Selected Components
- Biological · Drug
- Lead sponsor
- PharmAthene, Inc.
- Industry
- Eligibility
- 18 Years to 59 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Alcohol Withdrawal
- Interventions
- Ketamine, Dexmedetomidine, Normal saline
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 85 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Diabetes (DM)
- Interventions
- Glucagon, Saline (placebo)
- Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Type 2 Diabetes Mellitus, Obesity
- Interventions
- Niacin, Saline
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2021
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Safety, Tolerability, Pharmacokinetic Study in Healthy Volunteers
- Interventions
- Y-3 for injection, Placebo
- Drug
- Lead sponsor
- Neurodawn Pharmaceutical Co., Ltd.
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- Webster, Texas
- Conditions
- Chronic Pain
- Interventions
- Dexmedetomidine, Placebo Saline
- Drug · Other
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 83 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Acute Coronary Syndrome, Myocardial Infarction, Unstable Angina Pectoris
- Interventions
- Cardiac Computed Tomography
- Radiation
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 368 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2009
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Pouchitis, Irritable Pouch Syndrome
- Interventions
- Liraglutide Pen Injector, Placebo Pen Injector
- Drug
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Diffuse Cutaneous Systemic Sclerosis, Scleroderma, dcSSc
- Interventions
- Brentuximab Vedotin, Placebo
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 8
- States / cities
- Los Angeles, California • Washington D.C., District of Columbia • Ann Arbor, Michigan + 5 more
- Conditions
- Biliary Atresia
- Interventions
- Corticosteroids, Placebo
- Drug
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- Up to 6 Months
- Enrollment
- 141 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2013
- U.S. locations
- 14
- States / cities
- Los Angeles, California • San Francisco, California • Aurora, Colorado + 11 more
- Conditions
- Coronary Artery Disease, Diabetes Mellitus Type 2
- Interventions
- Glucagon-Like-Peptide-1/Regadenoson/Perflutren Lipid Microsphere
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 40 Years to 60 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2014
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Hantaan Virus Disease, Puumala Virus
- Interventions
- Hantaan virus vaccine (HTNV) - Using TriGrid Delivery System (TDS) for Intradermal Delivery (ID), Hantaan virus vaccine (HTNV) - Using TriGrid Delivery System (TDS) for Intramuscular Delivery (IM), Puumala virus vaccine (PUUV) - Using the TriGrid Delivery System (TDS) for Intradermal Delivery (ID), Puumala virus vaccine (PUUV) - Using the TriGrid Delivery System (TDS) for Intramuscular Delivery (IM), Hantaan/Puumala (HTNV/PUUV) virus vaccines - Using the TriGrid Delivery System (TDS) for Intradermal Delivery (ID), Hantaan/Puumala (HTNV/PUUV virus vaccines - Using the TriGrid Delivery System (TDS) for Intramusular Delivery (IM)
- Combination Product
- Lead sponsor
- U.S. Army Medical Research and Development Command
- Federal
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 61 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland